姓名：秦静波
职称： 助理研究员
电子邮件： qinjb6@mail.sysu.edu.cn
通讯地址： 珠海市香洲区梅华东路52号中山大学附属第五医院分子影像中心
学历和工作经历
2023/03-至今，中山大学附属第五医院 助理研究员
2020/08-2023/03，厦门大学，博士后
2014/09-2020/06，厦门大学，化学生物学，博士
2010/09-2014/06，中国药科大学，药学（基地班），学士
研究方向
1. 靶向核受体，激酶小分子药物的设计合成及作用机制研究
2. 细胞器靶向递送系统的研究
3. 药物筛选与转化研究
承担科研项目情况
在研科研项目
1. 国家自然科学基金青年科学基金项目, 22207093, 靶向核受体 Nur77 并诱导 KRAS 突变结直肠癌巨泡式死亡的小分子化合物的发现及作用机制研究, 2023-01-01至2025-12-30, 主持
代表性成果
近期代表性文章
1. Zihao Teng#, Chen Liu#, Xiangfu Du, Yuchen Guo, Zhenkun Huang, Jingya Gu, Xiaohui Chen,b Menghan Xiao, Shipeng Chen, Xiao-Bin Hao*, Jingbo Qin*, Shuaidong Huo*. Acid-Activated Mitochondria-Targeting Nanoprodrug for Reactive Oxygen Species (ROS)-Tolerant Cancer Therapy via Antioxidant Defense Inhibition. Journal of Controlled Release, 2025, 383, 113843.
2. Xiaohui Chen#, Remaihaba Kadier#, Mengting Shi#, Hongtao Chen, Kefeng Li, Yongzhen Xia, Rongna Li, Yili Long, Jingbo Qin*, Hao Wang*, Guan-min Jiang*. Targeting Melatonin To Mitochondria Mitigates Castration-resistant Prostate Cancer By Inducing Pyroptosis. Small, 2025, 2408996.
3. Xiaohui Chen #, Rongna Li#, Yingkun Qiu, Fanhong Li, Shutong Chen, Xiaodan Li, Hui Sun, Guanmin Jiang, Hua Fang*, Jingbo Qin*, Meijuan Fang*. Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl-pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel CDK9/HDAC inhibitors for cancer treatmen. Bioorganic Chemistry, 2025, 162, 108577.
4. Shengxian Zhao, Rongrong Zhang, Yule Xie, Xuejun Xu, Ke Lv, Yetao Chi, Jingbo Qin*, Hongyu Hu*. Synthesis and biological evaluation of 1-(4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl)-3-arylurea derivtives as anti-tumor modulators targeting Nur77. Journal of Molecular Structure, 2025, 1338, 142290.
5. YanfangGao#, YijingYang#, JingboQin#, MingyueYu, ShengweiHu, HaofanZhang, FanhongLin, HongyuHu*, MeijuanFang*, JinzhangZeng*. Design, synthesis, and biological evaluation of quinolinyl-ureido-phenyl-hydrazide derivatives and quinolinyl-hydrazide derivatives as anticancer agents targeting Nur77-mediated ferroptosis. European Journal of Medicinal Chemistry, 2025, 291,117559.
6. Zhixin Chen, Airun Zhang; Guanming Li; Chenshu Liu; Yuxia Chen; Jingbo Qin*; Ningning Li*; Xiaoyi Fang*. Discovery of triphenylphosphonium (TPP+)-conjugated GNX-865 and therapeutic hypothermia in neuron acute ischemia-reperfusion injury: the RISK pathway and mitochondrial permeability transition pore opening. Biochemical and Biophysical Research Communications, 2025, 766, 151886.
7. Yongzhen Xia#, Hongli Chen#, Jingbo Qin#, Weiyun Zhang, Huachun Gao, Xu Long, Hongying He, Lingyi Zhang, Chunxia Zhang, Chaoqun Cao, Lixue Yu, Xiaohui Chen*, Quancheng Chen*. The phthalide compound tokinolide B from Angelica sinensis exerts anti-inflammatory effects through Nur77 binding. Phytomedicine. 2024, 133, 155925.
8. Jingbo Qin#, Boning Niu#,Xiaohui Chen#, Cheng Hu, Sheng Lu, Hongsheng Li, Weihao Liu, Jiayi Li, Zihao Teng, Yinghuang Yang, Hongyu Hu, Yang Xu, Shuaidong Huo, Zhen Wu, Yingkun Qiu,* Hu Zhou,* and Meijuan Fang*. Discovery of 5‑(Pyrimidin-2-ylamino)‑1H‑indole-2-carboxamide Derivatives as Nur77 Modulators with Selective and Potent Activity Against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2023, 66, 23, 15847-15866.
9. Jingbo Qin#, Xiaohui Chen#, Weihao Liu#, Jun Chen, Weirong Liu, Yongzhen Xia, Zhehui Li, Mingyu Li, Shaojuan Wang, Quan Yuan, Yingkun Qiu *, Zhen Wu *, Meijuan Fang *. Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77. European Journal of Medicinal Chemistry, 2022, 244, 114849.
10. Jingbo Qin#, Jie Liu#, Chunxiao Wu, Jianwen Xu, Bowen Tang, Kaiqiang Guo, Xiaohui Chen, Weihao Liu, Tong Wu, Hu Zhou*, Meijuan Fang*, Zhen Wu*. Synthesis and biological evaluation of (3/4-(pyrimidin-2-ylamino)benzoyl)-based hydrazine-1-carboxam -ide/carbothioamide derivatives as novel RXRα antagonists. Journal of Enzyme Inhibition and Medicinal Chemistry 2020, 35 (1), 880-896.
11. Jingbo Qin#, Ningqiang Gong#, Zhihuan Liao, Shouwen Zhang, Peter Timashev, Shuaidong Huo* Xing-Jie Liang* Recent Progress in Mitochondria-Targeting-Based Nanotechnology for Cancer Treatment. Nanoscale 2021, 13, 7108.
近期代表性发明专利
1.一种三苯基膦修饰舍曲林衍生物及其制备方法和应用。CN202210214316.5；US202318349434A。
2．N-取代-5-((4-取代嘧啶-2-基)氨基)-1H-吲哚-2-甲酰胺衍生物。ZL202211044195.0。
3.嘧啶吲哚类Nur77受体调控剂及其制备方法和应用。专利授权号：ZL 201910105476.4。
4. N-取代-5-((4-取代嘧啶-2-基)氨基)吲哚类衍生物及其制备方法和用途。ZL 201710950061.8。
5. 1-(2-(碳酰肼取代基团)-1H-吲哚-5-基)-3-取代脲衍生物及制备方法 。专利授权号：ZL 201510749828.1。
